Checkpoint inhibitors in mesothelioma: hope for the future?

Affiliations

¹ Academic Respiratory Unit, Translational Health Sciences, University of Bristol Medical School, Southmead Hospital Bristol, Bristol BS10 5NB, UK. Electronic address: anna.bibby@bristol.ac.uk.
² Academic Respiratory Unit, Translational Health Sciences, University of Bristol Medical School, Southmead Hospital Bristol, Bristol BS10 5NB, UK.

Comment

Anna Bibby et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):172-174.

doi: 10.1016/S1470-2045(18)30868-4. Epub 2019 Jan 16.

¹ Academic Respiratory Unit, Translational Health Sciences, University of Bristol Medical School, Southmead Hospital Bristol, Bristol BS10 5NB, UK. Electronic address: anna.bibby@bristol.ac.uk.
² Academic Respiratory Unit, Translational Health Sciences, University of Bristol Medical School, Southmead Hospital Bristol, Bristol BS10 5NB, UK.

No abstract available

Comment on

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup. Scherpereel A, et al. Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Lancet Oncol. 2019. PMID: 30660609 Clinical Trial.